p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy

Breast Cancer Research

Volumn 8, Issue 6, 2006, Pages

  Frackelton Jr , A Raymond ^a,b   Lu, Li ^a   Davol, Pamela A ^a   Bagdasaryan, Robert ^a   Hafer, Laurie J ^c   Sgroi, Dennis C ^d  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c Catalyst Oncology Inc   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROTEIN P66; PROTEIN SHC; TAMOXIFEN; TYROSINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; PHOSPHOPROTEIN; SHC1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; RISK ASSESSMENT; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VALIDATION PROCESS; BIOSYNTHESIS; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; METABOLISM; PHOSPHORYLATION; TUMOR RECURRENCE; VALIDATION STUDY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; RECEPTORS, ESTROGEN; SHC SIGNALING ADAPTOR PROTEINS; TAMOXIFEN; TYROSINE;

EID: 34249105040     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1631     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0 15894097
2. Hayes DF Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst 2004, 96:895-897. 15199102
3. Ring A Dowsett M Mechanisms of tamoxifen resistance Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776 15613444
4. Jaiyesimi IA Buzdar AU Decker DA Hortobagyi GN Use of tamoxifen for breast cancer: Twenty-eight years later J Clin Oncol 1995, 13:513-529. 7844613
5. Shou J Massarweh S Osborne CK Wakeling AE Ali S Weiss H Schiff R Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 2004, 96:926-935. 15199112
6. Kelly MJ Levin ER Rapid actions of plasma membrane estrogen receptors Trends Endocrinol Metab 2001, 12:152-156. 10.1016/S1043-2760(01)00377-0 11295570
7. Razandi M Alton G Pedram A Ghonshani S Webb P Levin ER Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane Mol Cell Biol 2003, 23:1633-1646. 151696 12588983 10.1128/MCB.23.5.1633-1646.2003
8. Bunone G Briand PA Miksicek RJ Picard D Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation Embo J 1996, 15:2174-2183. 450141 8641283
9. Osborne CK Shou J Massarweh S Schiff R Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 2005, 11:865s-870s. 15701879
10. Ravichandran KS Signaling via Shc family adapter proteins Oncogene 2001, 20:6322-6330. 10.1038/sj.onc.1204776 11607835
11. Filardo EJ Thomas P GPR30: A seven-transmembrane-spanning estrogen receptor that triggers EGF release Trends Endocrinol Metab 2005, 16:362-367. 10.1016/j.tem.2005.08.005 16125968
12. Zhang Z Kumar R Santen RJ Song RX The role of adapter protein Shc in estrogen non-genomic action Steroids 2004, 69:523-529. 10.1016/ j.steroids.2004.05.012 15288764
13. Rozakis-Adcock M McGlade J Mbamalu G Pelicci G Daly R Li W Batzer A Thomas S Brugge J Pelicci PG Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases Nature 1992, 360:689-692. 10.1038/360689a0 1465135
14. Pelicci G Lanfrancone L Grignani F McGlade J Cavallo F Forni G Nicoletti I Grignani F Pawson T Pelicci PG A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction Cell 1992, 70:93-104. 10.1016/0092-8674(92)90536-L 1623525
15. Segatto O Pelicci G Giuli S Digiesi G Di Fiore PP McGlade J Pawson T Pelicci PG Shc products are substrates of erbB-2 kinase Oncogene 1993, 8:2105-2112. 8101647
16. Migliaccio E Mele S Salcini AE Pelicci G Lai KM Superti-Furga G Pawson T Di Fiore PP Lanfrancone L Pelicci PG Opposite effects of the p52shc/ p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway Embo J 1997, 16:706-716. 1169672 9049300 10.1093/ emboj/16.4.706
17. Okada S Kao AW Ceresa BP Blaikie P Margolis B Pessin JE The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway J Biol Chem 1997, 272:28042-28049. 10.1074/jbc.272.44.28042 9346957
18. Migliaccio E Giorgio M Pelicci PG Apoptosis and aging: Role of p66(Shc) redox protein Antioxid Redox Signal 2006, 8:600-608. 10.1089/ ars.2006.8.600 16677103
19. Pertschuk LP Eisenberg KB Carter AC Feldman JG Heterogeneity of estrogen binding sites in breast cancer: Morphologic demonstration and relationship to endocrine response Breast Cancer Res Treat 1985, 5:137-147. 10.1007/BF01805987 3893573
20. Ma XJ Wang Z Ryan PD Isakoff SJ Barmettler A Fuller A Muir B Mohapatra G Salunga R Tuggle JT A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 2004, 5:607-616. 10.1016/j.ccr.2004.05.015 15193263
21. Davol PA Bagdasaryan R Elfenbein GJ Maizel AL Frackelton AR Jr Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer Cancer Res 2003, 63:6772-6783. 14583473
22. Linke SP Bremer TM Herold CD Sauter G Diamond C A multimarker model to predict outcome in tamoxifen-treated breast cancer patients Clin Cancer Res 2006, 12:1175-1183. 10.1158/1078-0432.CCR-05-1562 16489071
23. Brenton JD Carey LA Ahmed AA Caldas C Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005, 23:7350-7360. 10.1200/JCO.2005.03.3845 16145060
24. Bossard N Descotes F Bremond AG Bobin Y De Saint Hilaire P Golfier F Awada A Mathevet PM Berrerd L Barbier Y Esteve J Keeping data continuous when analyzing the prognostic impact of a tumor marker: An example with cathepsin D in breast cancer Breast Cancer Res Treat 2003, 82:47-59. 10.1023/B:BREA.0000003919.75055.e8 14672403
25. DiGiovanna MP Stern DF Edgerton SM Whalen SG Moore D 2nd Thor AD Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients J Clin Oncol 2005, 23:1152-1160. 10.1200/JCO.2005.09.055 15718311
26. Arpino G Weiss H Lee AV Schiff R De Placido S Osborne CK Elledge RM Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 2005, 97:1254-1261. 16145046
27. Mandlekar S Kong AN Mechanisms of tamoxifen-induced apoptosis Apoptosis 2001, 6:469-477. 10.1023/A:1012437607881 11595837
28. Magne N Toillon RA Castadot P Ramaioli A Namer M Different clinical impact of estradiol receptor determination according to the analytical method: A study on 1940 breast cancer patients over a period of 16 consecutive years Breast Cancer Res Treat 2006, 95:179-184. 10.1007/ s10549-005-9065-z 16317583
29. Pichon MF Broet P Magdelenat H Delarue JC Spyratos F Basuyau JP Saez S Rallet A Courriere P Millon R Asselain B Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers Br J Cancer 1996, 73:1545-1551. 8664127